绿叶制药新药物LY03020获FDA许可开展临床试验
财中社1月15日电绿叶制药（02186）发布公告，本集团自主开发的新一代抗精神病药物LY03020已获得美国食品药品监督管理局（FDA）许可开展临床试验，拟用于治疗精神分裂症。LY03020基于本集团的新分子实体/新治疗实体技术平台开发，成为全球首个痕量胺相关受体1（TAAR1）和5-羟色胺2C受体（5-HTR）的双靶点激动剂。此外，LY03020也在中国进入临床阶段。
精神分裂症是一种严重的精神疾病，全球和美国分别影响约2400万人和370万人。约30%的难治性精神分裂症患者在使用传统的一代和二代抗精神病药物时效果不佳，因此新一代抗精神分裂症药物被寄予厚望。LY03020通过激动突触前膜的机制，有望减少不良反应并显著改善患者的阳性、阴性症状及认知症状等。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10